IS8521A - Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi - Google Patents
Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á AlzheimerssjúkdómiInfo
- Publication number
- IS8521A IS8521A IS8521A IS8521A IS8521A IS 8521 A IS8521 A IS 8521A IS 8521 A IS8521 A IS 8521A IS 8521 A IS8521 A IS 8521A IS 8521 A IS8521 A IS 8521A
- Authority
- IS
- Iceland
- Prior art keywords
- disease
- treatment
- alzheimer
- beta
- tricyclic indole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0328900.6A GB0328900D0 (en) | 2003-12-12 | 2003-12-12 | Novel compounds |
| PCT/EP2004/014076 WO2005058915A1 (fr) | 2003-12-12 | 2004-12-09 | Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8521A true IS8521A (is) | 2006-06-26 |
Family
ID=30130158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8521A IS8521A (is) | 2003-12-12 | 2006-06-26 | Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070073060A1 (fr) |
| EP (1) | EP1692143B1 (fr) |
| JP (1) | JP2007513913A (fr) |
| KR (1) | KR20060121164A (fr) |
| CN (1) | CN1914214A (fr) |
| AT (1) | ATE414090T1 (fr) |
| AU (1) | AU2004299231A1 (fr) |
| BR (1) | BRPI0417476A (fr) |
| CA (1) | CA2549072A1 (fr) |
| DE (1) | DE602004017777D1 (fr) |
| GB (1) | GB0328900D0 (fr) |
| IL (1) | IL175819A0 (fr) |
| IS (1) | IS8521A (fr) |
| MA (1) | MA28241A1 (fr) |
| NO (1) | NO20063137L (fr) |
| RU (1) | RU2006124863A (fr) |
| WO (1) | WO2005058915A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050239836A1 (en) | 2004-03-09 | 2005-10-27 | Varghese John | Substituted hydroxyethylamine aspartyl protease inhibitors |
| US7385085B2 (en) | 2004-07-09 | 2008-06-10 | Elan Pharmaceuticals, Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
| BRPI0515383A (pt) * | 2004-09-21 | 2008-07-22 | Pfizer Prod Inc | n-etil hidroxietilamina útil no tratamento de condições do snc |
| GB0422766D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| GB0422765D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| WO2007047305A1 (fr) * | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Procedes de traitement de l'amyloïdose en utilisant des derives de cyclopropyle inhibiteurs de l'aspartyle-protease |
| US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
| US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
| FR2919285B1 (fr) | 2007-07-27 | 2012-08-31 | Sanofi Aventis | Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique. |
| FR2919288B1 (fr) * | 2007-07-27 | 2009-09-04 | Sanofi Aventis Sa | Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique. |
| FR2919289B1 (fr) * | 2007-07-27 | 2009-09-04 | Sanofi Aventis Sa | Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique. |
| FR2919286A1 (fr) | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| NZ582871A (en) * | 2007-07-27 | 2011-09-30 | Sanofi Aventis | 1,2,3,4-Tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5- tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof |
| NZ588715A (en) * | 2008-05-29 | 2012-11-30 | Albany Molecular Res Inc | 5-ht3 receptor modulators, methods of making, and use thereof |
| FR2960876B1 (fr) | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| AU2011261375B2 (en) | 2010-06-04 | 2016-09-22 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| BR112015003824B1 (pt) * | 2012-08-24 | 2022-10-04 | Treventis Corporation | Composto, composição farmacêutica e uso do composto |
| WO2019075358A1 (fr) * | 2017-10-13 | 2019-04-18 | Ghosh Arun K | Inhibiteurs de bace1 pour le traitement de la maladie d'alzheimer |
| US12043631B2 (en) | 2017-10-13 | 2024-07-23 | Purdue Research Foundation | BACE1 inhibitors for the treatment of Alzheimer's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998033795A1 (fr) * | 1997-02-04 | 1998-08-06 | The Regents Of The University Of California | Inhibiteurs de cathepsine d nanomolaires et non peptidiques |
| US6207664B1 (en) * | 1998-11-25 | 2001-03-27 | Pfizer Inc. | Squalene synthetase inhibitor agents |
| DE60124080T2 (de) * | 2000-03-23 | 2007-03-01 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit |
| EP1299352B1 (fr) * | 2000-06-30 | 2005-12-28 | Elan Pharmaceuticals, Inc. | Composes pour traiter la maladie d'alzheimer |
| US7176242B2 (en) * | 2001-11-08 | 2007-02-13 | Elan Pharmaceuticals, Inc. | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives |
| GB0228410D0 (en) * | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
| GB0309221D0 (en) * | 2003-04-23 | 2003-06-04 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-12-12 GB GBGB0328900.6A patent/GB0328900D0/en not_active Ceased
-
2004
- 2004-12-09 AT AT04803724T patent/ATE414090T1/de not_active IP Right Cessation
- 2004-12-09 JP JP2006543488A patent/JP2007513913A/ja not_active Withdrawn
- 2004-12-09 EP EP04803724A patent/EP1692143B1/fr active Active
- 2004-12-09 KR KR1020067011376A patent/KR20060121164A/ko not_active Application Discontinuation
- 2004-12-09 DE DE602004017777T patent/DE602004017777D1/de not_active Expired - Fee Related
- 2004-12-09 US US10/596,296 patent/US20070073060A1/en not_active Abandoned
- 2004-12-09 BR BRPI0417476-3A patent/BRPI0417476A/pt not_active IP Right Cessation
- 2004-12-09 AU AU2004299231A patent/AU2004299231A1/en not_active Abandoned
- 2004-12-09 CA CA002549072A patent/CA2549072A1/fr not_active Abandoned
- 2004-12-09 RU RU2006124863/04A patent/RU2006124863A/ru not_active Application Discontinuation
- 2004-12-09 WO PCT/EP2004/014076 patent/WO2005058915A1/fr active Application Filing
- 2004-12-09 CN CNA2004800416435A patent/CN1914214A/zh active Pending
-
2006
- 2006-05-22 IL IL175819A patent/IL175819A0/en unknown
- 2006-06-26 IS IS8521A patent/IS8521A/xx unknown
- 2006-06-26 MA MA29143A patent/MA28241A1/fr unknown
- 2006-07-06 NO NO20063137A patent/NO20063137L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB0328900D0 (en) | 2004-01-14 |
| JP2007513913A (ja) | 2007-05-31 |
| ATE414090T1 (de) | 2008-11-15 |
| DE602004017777D1 (de) | 2008-12-24 |
| US20070073060A1 (en) | 2007-03-29 |
| RU2006124863A (ru) | 2008-01-20 |
| EP1692143B1 (fr) | 2008-11-12 |
| CN1914214A (zh) | 2007-02-14 |
| BRPI0417476A (pt) | 2007-05-08 |
| CA2549072A1 (fr) | 2005-06-30 |
| EP1692143A1 (fr) | 2006-08-23 |
| WO2005058915A1 (fr) | 2005-06-30 |
| KR20060121164A (ko) | 2006-11-28 |
| MA28241A1 (fr) | 2006-10-02 |
| IL175819A0 (en) | 2006-10-05 |
| AU2004299231A1 (en) | 2005-06-30 |
| NO20063137L (no) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8521A (is) | Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi | |
| IS7925A (is) | Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm | |
| BRPI0409622A (pt) | derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer | |
| CY1111086T1 (el) | Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace) | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| WO2004080376A3 (fr) | Nouveaux composes | |
| ATE396973T1 (de) | Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| EP1817312A4 (fr) | Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| WO2007019078A3 (fr) | Inhibiteurs de la beta-secretase tricyclique pour traiter la maladie d'alzheimer | |
| ATE519740T1 (de) | Tetrahydroindolderivate zur behandlung von alzheimer-krankheit | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| EP1912963A4 (fr) | Inhibiteurs de beta-secretase a cetal cyclique destines au traitement de la maladie d'alzheimer | |
| IL165996A0 (en) | Novel thiophene acyl hydrazino derivatives method for preparing same use thereof as medicines pharmaceutical compositions and novel use |